SOPHiA GENETICS S.A.

NASDAQ:SOPH

Medical - Healthcare Information Services

Healthcare
$7.47 +0.38%

+$0.02 today

Market cap
$635.90M
Beta
0.98
P/E (TTM)
-4.6
EPS (TTM)
-$1.14
52W Low $2.59High $5.70

Volume 0.61M

Average 0.10M

SOPH Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

SOPHiA GENETICS S.A.NASDAQ: SOPH

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures declines year over year

Q1 FY2026 capital expenditures of $878K (cash outflow) fell 41.1% year over year, ahead of the -57.1% change in trailing-twelve-month capital expenditures. Sequentially, it rose 152.0% from the prior quarter. Over 3 fiscal years it compounded at -61.9% a year.

Context

  • Capital expenditures amounted to 0.7% of revenue in FY2025, down 11.8 pp from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -41.1% holds above the trailing-twelve-month pace of -57.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$878K+152.0% QoQ
Last fiscal yearDec 2025
-$574K-93.0% YoY
LTMMar 2026
-$3.31M-57.1% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.1%——
1 year-93.0%——
3-year CAGR-61.9%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(574K) USD
Year-over-year change
+93.0%

Capital Expenditures vs competitors

How SOPH compares with its peers on the latest reported figures

  • SOPH's LTM Mar 2026 capital expenditures of $3.31M is the 7th largest of the 10 companies compared; the peer median is $5.19M.
  • Its year-over-year change of -57.1% is the 5th highest of 9, against a peer median of -46.2%.
  • Capital expenditures amounts to 4.1% of revenue for SOPH, versus a peer median of 2.0%.
SOPH Competitors Peer median
Capital Expenditures for SOPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TEMTempus AI, Inc.LTM Sep 2026$30M +3.8%+14.1%2.0%
BLLNBillionToOne, Inc.LTM Jun 2026$12.18M ——3.1%
HCATHealth Catalyst, Inc.LTM Mar 2026$9.79M -31.3%-61.8%3.2%
NRCNational Research CorporationLTM Mar 2026$9.55M -33.2%+2.9%6.9%
PSNLPersonalis, Inc.LTM Mar 2026$5.19M +29.3%-55.1%8.0%
HSTMHealthStream, Inc.LTM Mar 2026$3.37M -59.2%+27.7%1.1%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$3.31M -57.1%-61.9%4.1%
DHDefinitive Healthcare Corp.LTM Mar 2026$2.22M -88.8%+26.2%0.9%
CERTCertara, Inc.LTM Mar 2026$1.79M -85.3%+7.2%0.4%
OPRXOptimizeRx CorporationLTM Mar 2026$52K -84.0%-38.1%0.0%
Peer median (excluding SOPH) $5.19M-46.2%+5.0%2.0%

Competitors are the stored peer set for SOPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.51M)(87.59M)(78.5M)(61.27M)(79M)
Depreciation & Amortization3.61M5.57M8.34M8.6M9.53M
Deferred Income Tax(1.6M)(1.29M)(1.13M)(726K)0
Stock-Based Compensation8.51M13.61M15.24M16.49M0
Change in Working Capital6.12M(1.27M)872K(2.58M)10.71M
Accounts Receivables1.81M1.33M(6.5M)5.89M(6.6M)
Inventory(2.34M)(200K)(874K)69K46K
Accounts Payables8.98M(1.43M)6.87M(7.39M)16.93M
Other Working Capital(2.33M)(977K)1.38M(1.16M)334K
Other Non-Cash Items(1.08M)873K6.6M(3.33M)20.75M
Operating Cash Flow(57.94M)(70.09M)(48.58M)(42.82M)(38.01M)
Capital Expenditures(6.67M)(10.38M)(9.23M)(8.18M)(574K)
Acquisitions (Net)3.99M0000
Purchases of Investments(72.14M)(26.18M)00(1.89M)
Sales of Investments21.88M78.53M17.55M00
Other Investing Activities(3.99M)(6.28M)(7.73M)(7.93M)0
Investing Cash Flow(56.93M)41.97M8.32M(8.18M)(10.51M)
Debt Repayment(4.09M)(2.32M)(3.04M)11.18M32.69M
Common Stock Issued231.31M00405K1.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities10.55M748K226K00
Financing Cash Flow237.77M(1.57M)(2.82M)11.59M34.13M
Effect of Forex Changes(4.56M)(1.97M)5.02M(3.61M)4.45M
Net Change in Cash118.34M(31.66M)(38.05M)(43.03M)(9.94M)
Free Cash Flow(64.61M)(80.47M)(57.8M)(51M)(38.59M)

SOPHiA GENETICS S.A.

NASDAQ:SOPH

Intrinsic Alpha fair value

Locked

Current Price

$7.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.